ClinicalTrials.gg

Precursor Cell Lymphoblastic Leukemia-Lymphoma clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 2,586 studies for Precursor Cell Lymphoblastic Leukemia-Lymphoma across more than 10 countries. 475 are recruiting or about to start. 1,226 of them are mainly about Precursor Cell Lymphoblastic Leukemia-Lymphoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 2 narrower conditions too, such as Precursor T-Cell Lymphoblastic Leukemia-Lymphoma: 2,766 studies, 533 open.

ClinicalTrials.gov finds 2,969 studies for Precursor Cell Lymphoblastic Leukemia-Lymphoma. How that becomes 2,585 here

This page counts the studies the registry files under Precursor Cell Lymphoblastic Leukemia-Lymphoma, and those it files under no condition that list Precursor Cell Lymphoblastic Leukemia-Lymphomathemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 16, 2026. How condition pages count

  1. 2,969Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −179Filed under a narrower condition, counted on its own pagePrecursor T-Cell Lymphoblastic Leukemia-Lymphoma 160 · Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 18
  3. −213List Precursor Cell Lymphoblastic Leukemia-Lymphoma as a condition, but the registry did not file them under itMost often written as “B-cell Acute Lymphoblastic Leukemia” (84), “B Acute Lymphoblastic Leukemia” (21), and “Recurrent B Acute Lymphoblastic Leukemia” (16). The registry filed them under other conditions only, most often Burkitt Lymphoma (180) and Recurrence (34).
  4. −47Match it another way30 name it in the title, 14 in a keyword, and 3 by a synonym or other text the search reads.
  5. 2,530Counted here and found by its search7 of them list Precursor Cell Lymphoblastic Leukemia-Lymphoma in their own words; the registry filed them under no condition.
  6. +55
    Counted here, but its search does not find themThe first 20 of 55.
  7. 2,585The count on this page

Status

Completed
1,307
Recruiting
372
Terminated
298
Status unknown
240
Active, not recruiting
153
Withdrawn
93

Phase

Phase 2
927
Phase 1
855
Phase 3
203
Phase 4
63
Early Phase 1
41

Where

United States
1,545
China
232
Canada
172
France
152
Italy
148
Germany
130

Who develops what

Add Precursor Cell Lymphoblastic Leukemia-Lymphoma to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 14 programs from 12 companies, 8 with this as their studies’ main aim; 1 with a live phase 3 study; 0 primary completions in the next 12 months. Compare AstraZeneca, PersonGen BioTherapeutics (Suzhou) and Amgen here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
DexamethasoneRecent, repeated
Evidence
  • NCT07770698 · BeOne Medicines · Phase 2 · live · background · “Dexamethasone” · registered May 2026
  • NCT07387926 · Novartis · Phase 2 · live · background · “Dexamethasone” · registered Jan 2026
  • NCT03589326 · Takeda · Phase 3 · live · background · “Dexamethasone” · registered Jul 2018
  • NCT03476239 · Amgen · Phase 3 · background · “Dexamthasone” · registered Mar 2018
  • NCT02393859 · Amgen · Phase 3 · comparator · “Dexamethasone” · registered Mar 2015
AbbVie11% of its industry studiesUS: off-patent, 28 generics marketedEU: Norgine (EMA 2016)22 studies

17 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
blinatumomabApproved: EU 2015☆ Track2 live phase-3 studies: NCT07223190, NCT04994717Amgen

The 1 in phase 3 with the nearest primary completion, of 14 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (0)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

None in the next 12 months.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Precursor Cell Lymphoblastic Leukemia-Lymphoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Alkylating agents 35 open · Antimetabolites 34 open · Tyrosine kinase inhibitors (TKIs) 24 open · Corticosteroids 11 open · Antibody-drug conjugates (ADCs) 7 open

Coming up

167studies finish main data collection within a year10 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 372 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 259 (70%) stop at 75 or younger. 248 (67%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 29 (8%) take healthy volunteers.

Recruiting studies that take each age, of 372
AgeWomenMen
10202 (54%)202 (54%)
18331 (89%)331 (89%)
30238 (64%)238 (64%)
40227 (61%)227 (61%)
50219 (59%)219 (59%)
65195 (52%)195 (52%)
75140 (38%)140 (38%)
85105 (28%)105 (28%)

Across all 2,586 studies, recruiting or not: 57% stop at 75 or younger and 46% at 65; 58% take children; <1% are for women only and <1% for men only; 7% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Precursor Cell Lymphoblastic Leukemia-Lymphoma studies take

Of 228 phase 2 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 74 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 157 mo35–92 · 209 studies49 mo30–65 · 50 studies57 mo38–92 · 159 studies
Phase 1/279 mo56–119 · 114 studies—75 mo57–119 · 81 studies
Phase 274 mo42–120 · 228 studies—79 mo43–120 · 210 studies
Phase 386 mo46–104 · 59 studies—95 mo65–109 · 43 studies
Phase 469 mo27–123 · 30 studies——
Interventional, no phase32 mo12–66 · 214 studies—33 mo12–66 · 207 studies
Observational54 mo24–142 · 163 studies—54 mo26–143 · 145 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Stopped1

Studies

Recruiting first, then most recently updated. Showing 50 of 2,586. Browse all 2,586 → or search them.